{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T22:49:06Z","timestamp":1759963746838,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.jaad.2014.01.879","type":"journal-article","created":{"date-parts":[[2014,6,17]],"date-time":"2014-06-17T04:59:43Z","timestamp":1402981183000},"page":"11.e1-11.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Proactive infectious disease approach to dermatologic patients who are taking tumor necrosis factor\u2013alfa antagonists"],"prefix":"10.1016","volume":"71","author":[{"given":"Lisa M.","family":"Chirch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip R.","family":"Cataline","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin D.","family":"Dieckhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane M.","family":"Grant-Kels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2014.01.879_bib1","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.idc.2011.08.002","article-title":"Biologics and infections: lessons from tumor necrosis factor blocking agents","volume":"25","author":"Wallis","year":"2011","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.jaad.2014.01.879_bib2","first-page":"683","article-title":"Tuberculosis associated with blocking agents against tumor necrosis factor-alpha\u2014California, 2002-2003","volume":"53","year":"2004","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2014.01.879_bib3","first-page":"1","article-title":"Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection\u2014United States, 2010","volume":"59","author":"Mazurek","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jaad.2014.01.879_bib4","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2133.2009.09331.x","article-title":"Tuberculosis screening in patients with\u00a0psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test","volume":"161","author":"Laffitte","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.01.879_bib5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1086\/648724","article-title":"Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy","volume":"50","author":"Hage","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2014.01.879_bib6","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/art.20454","article-title":"Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists","volume":"50","author":"Bergstrom","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2014.01.879_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2036.2009.04112.x","article-title":"Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease","volume":"31","author":"Shale","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jaad.2014.01.879_bib8","doi-asserted-by":"crossref","first-page":"410521","DOI":"10.1155\/2013\/410521","article-title":"Long term safety of anti-TNF adalimumab in HBc antibody-positive psoriatic arthritis patients: a retrosepctive case series of 8 patients","volume":"2013","author":"Laurenti","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.jaad.2014.01.879_bib9","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jaad.2005.11.1035","article-title":"Etanercept therapy in two patients with psoriasis and concomitant hepatitis C","volume":"54","author":"De Simone","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.01.879_bib10","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jaad.2005.05.043","article-title":"Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection","volume":"54","author":"Rokhsar","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.01.879_bib11","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jaad.2004.05.013","article-title":"Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases","volume":"51","author":"Magliocco","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.01.879_bib12","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/ard.2007.081513","article-title":"The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease","volume":"67","author":"Cepeda","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2014.01.879_bib13","unstructured":"AIDSinfo web site. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at: http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf. Accessed March 23, 2014."},{"key":"10.1016\/j.jaad.2014.01.879_bib14","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1128\/CMR.17.1.208-217.2004","article-title":"Strongyloides stercoralis in the immunocompromised population","volume":"17","author":"Keiser","year":"2004","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jaad.2014.01.879_bib15","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/ajg.2009.733","article-title":"A practical guide\u00a0to vaccinating the inflammatory bowel disease patient","volume":"105","author":"Wasan","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaad.2014.01.879_bib16","first-page":"2","article-title":"Practical use of biologic therapy in dermatology: some considerations and checklists","volume":"18","author":"Ortleb","year":"2012","journal-title":"Dermatol Online J"},{"year":"2006","key":"10.1016\/j.jaad.2014.01.879_bib17"},{"key":"10.1016\/j.jaad.2014.01.879_bib18","unstructured":"Centers for Disease Control and Prevention web site. Vaccines and immunizations. Available at: http:\/\/www.cdc.gov\/vaccines\/vpd-vac\/shingles\/vacc-need-know.htm. Accessed March 23, 2014."},{"key":"10.1016\/j.jaad.2014.01.879_bib19","first-page":"1","article-title":"Epidemiology and prevention of vaccine-preventable diseases","volume":"60","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2014.01.879_bib20","first-page":"816","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"61","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2014.01.879_bib21","first-page":"626","article-title":"FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP)","volume":"59","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2014.01.879_bib22","first-page":"630","article-title":"FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP)","volume":"59","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2014.01.879_bib23","first-page":"1705","article-title":"Recommendations on the use of quadrivalent human papillomavirus vaccine in males\u2014Advisory Committee on Immunization Practices (ACIP), 2011","volume":"60","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2014.01.879_bib24","first-page":"9","article-title":"Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years and older\u2014United States, 2013","volume":"62","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096221401010X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096221401010X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:30:41Z","timestamp":1759271441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096221401010X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S019096221401010X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2014.01.879","relation":{},"ISSN":["0190-9622"],"issn-type":[{"type":"print","value":"0190-9622"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proactive infectious disease approach to dermatologic patients who are taking tumor necrosis factor\u2013alfa antagonists","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2014.01.879","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}